Physician profile
Melanie E Watkins
NPI 1639357767
$7,937.37
in general payments reported to CMS, 2019-2025
28 companies · $2,696 in 2025
The $2,696 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $193 · 2021: $158 · 2023: $202 · 2024: $4,286 · 2025: $2,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,400 · Food and Beverage: $571 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,400.00 |
| Food and Beverage | $571.28 |
| Education | $212.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $6,413.21 | 2024-2025 | |
| Astellas Pharma US INC | $319.77 | 2021-2025 | Veozah |
| Coopersurgical, INC. | $167.66 | 2019 | |
| Novo Nordisk INC | $163.18 | 2023-2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $153.49 | 2019-2021 | |
| Abbvie INC. | $105.26 | 2019-2021 | |
| Therapeuticsmd, INC. | $88.94 | 2019-2021 | |
| Hologic Sales and Service, LLC | $63.04 | 2019-2024 | Aptima |
| Organon LLC | $45.52 | 2024-2025 | Jada System |
| Millicent US INC | $35.53 | 2024 | Femring, Intrarosa |
| Exeltis, USA INC. | $35.50 | 2020-2024 | Slynd |
| Mayne Pharma Commercial LLC | $32.59 | 2023 | |
| Biogen, INC. | $27.43 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $27.21 | 2019 | |
| Dexcom, INC. | $25.75 | 2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $25.09 | 2023 | Balcoltra |
| Vivus LLC | $22.90 | 2023 | Qsymia |
| Lupin INC. | $22.18 | 2020 | |
| Agile Therapeutics, INC. | $21.86 | 2021 | |
| Ethicon US, LLC | $20.80 | 2019 | |
| Baxter Healthcare | $19.84 | 2024 | Perclot |
| Lilly USA, LLC | $16.89 | 2025 | Zepbound |
| Mylan Pharmaceuticals INC. | $16.29 | 2020 | |
| Alydia Health | $15.95 | 2021 | |
| Covidien LP | $14.56 | 2019 | |
| Allergan, INC. | $12.77 | 2019 | |
| Amgen INC. | $12.36 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.